AAV-miniBEND(mPro723)-Cre-P2A-EGFP-bGHpA_mCis700

Research background

This AAV provides recombinase-based genetic access, enabling conditional control of downstream payloads in genetically defined cells. Recombinase tools are widely used to restrict expression, create intersectional logic, or enable lineage/cell-type targeting.

Mechanism and expected readouts

Recombinase expression catalyzes site-specific DNA recombination at matching target sites, permanently switching genetic states in infected cells. This can gate expression of FLEX/DIO payloads or enable intersectional strategies when combined with other recombinases.

Expression design and interpretation

Expression is driven by the miniBEND(mPro723) promoter, which determines where and how strongly the payload is expressed in your system (cell populations defined by the listed promoter). The construct's regulatory logic controls where/when the payload is active; expression is constitutive (no recombinase or inducer required). A built-in reporter/tag supports validation and localization; EGFP provides a green fluorescent protein (Ex ~488 nm / Em ~507 nm) readout for expression, morphology, and targeting validation. The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control).

Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.

Common research applications

• Conditional targeting for cell-type or projection-specific experiments
• Intersectional labeling or manipulation strategies
• Permanent genetic switching for lineage or fate-mapping workflows

Experimental considerations

• Verify recombination efficiency with a compatible reporter in your system
• Account for irreversible switching when designing longitudinal studies
• Use appropriate negative controls (no recombinase or mismatched recombinase lines)

Controls and validation

Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.

• Sales Terms and Conditions (PDF)
• SDS (PDF)

At present, the main purification approaches for rAAV include:

• Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
• Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
• Chromatographic purification methods, primarily based on affinity and ion-exchange principles.

Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.

Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.